+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

  • ID: 4745165
  • Report
  • Region: Global
  • 140 Pages
  • GBI Research
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Allergan Plc
  • Bayer AG
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer
  • MORE

Summary
The women's health market represents a small but growing therapy area. There are currently 277 pipeline products in active development for women’s health, making it the 16th largest therapy area by pipeline size. Key indications within the area include endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia, menopausal disorders and infertility.

The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024. This relatively strong growth will be driven by a number of factors. These include the strong growth projected for human papillomavirus (HPV) vaccines, which are administered to girls and women in order to prevent development of CIN, an abnormality of the cells on the surface of the cervix, which can progress to cervical cancer in some cases.

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

Some 246 licensing deals have been completed within the women’s health therapy area since 2006, demonstrating a relatively high level of activity, considering the small size of the therapy area. Co-development deal activity has been much lower, with only 78 deals completed since 2006.

The strategic consolidations landscape was largely dominated by small molecule products and products acting on G-protein coupled receptors (GPCR). The majority of deals identified were relatively low value although a small number of deals exceeded $500m in value, demonstrating that women’s health products are capable of attracting high levels of investment.

The report ""Global Women’s Health Drugs Market to 2024  Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth"" covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

Scope

  • There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
  • Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
  • Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
  • The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
  • In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Reasons to buy

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drugs mechanism of action.
  • Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
  • Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
  • Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Allergan Plc
  • Bayer AG
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Overview
2.1.1 Endometriosis
2.1.2 Polycystic Ovarian Syndrome
2.1.3 Cervical Intraepithelial Neoplasia
2.1.4 Menopausal Disorders
2.1.5 Infertility
2.2 Symptoms
2.2.1 Endometriosis
2.2.2 Polycystic Ovarian Syndrome
2.2.3 Cervical Intraepithelial Neoplasia
2.2.4 Menopausal Disorders
2.2.5 Infertility
2.3 Diagnosis
2.3.1 Endometriosis
2.3.2 Polycystic Ovarian Syndrome
2.3.3 Cervical Intraepithelial Neoplasia
2.3.4 Menopausal Disorders
2.3.5 Infertility
2.4 Etiology and Epidemiology
2.4.1 Endometriosis
2.4.2 Polycystic Ovarian Syndrome
2.4.3 Cervical Intraepithelial Neoplasia
2.4.4 Menopause
2.4.5 Infertility
2.5 Pathophysiology
2.5.1 Endometriosis
2.5.2 Polycystic Ovarian Syndrome
2.5.3 Cervical Intraepithelial Neoplasia
2.6 Co-morbidities and Complications
2.6.1 Endometriosis
2.6.2 Polycystic Ovarian Syndrome
2.6.3 Cervical Intraepithelial Neoplasia
2.6.4 Menopause and Menopausal Disorders
2.6.5 Infertility
2.7 Treatment
2.7.1 Treatment Options

3 Key Marketed Products
3.1 Overview
3.2 Premarin family (conjugated estrogens) - Pfizer
3.3 Lupron/Lupron Depot (leuprolide acetate SR) - AbbVie
3.4 Gonal-F (follitropin alfa) - Merck KGaA
3.5 Mirena (levonorgestrel) - Bayer
3.6 Celebrex (celecoxib) - Pfizer
3.7 Implanon/Nexplanon (etonogestrel) - Merck & Co.
3.8 Yasmin/Yaz (drospirenone and ethinylestradiol) - Bayer
3.9 Nuvaring (ethinylestradiol and etonogestrel) - Merck & Co
3.10 Gardasil - Merck and Co
3.11 Esmya (ulipristal acetate) - Gedoen Richter/Allergan
3.12 Orilissa (elagolix sodium) - AbbVie

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.5 Assessment of Key Pipeline Products
4.5.1 Relugolix - Takeda Pharmaceutical Co. Ltd
4.5.2 Bremelanotide - AMAG Pharmaceuticals Inc
4.5.3 SAGE-217 - Sage Therapeutics Inc.
4.5.4 Fezolinetant - Ogeda SA
4.5.5 Zulresso - Sage Therapeutics
4.5.6 Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid - Inovio Pharmaceuticals Inc
4.5.7 Retosiban - GlaxoSmithKline

5 Multi-scenario Market Forecast to 2024
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target Class
5.3.1 G Protein-Coupled Receptor
5.3.2 Nuclear Receptor
5.3.3 Pathogen
5.3.4 Ion Channels/Transporter

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Bayer AG - Company to Remain a Market Leader within Women’s Health
6.1.2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
6.1.3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
6.1.4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 
6.1.5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6.1.6 Pfizer - How will patent expiration affect revenues for women’s health market?
6.1.7 TherapeuticsMD - Women’s Health Specialist to Gain Considerable Market Share by 2024
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value and Year
7.1.2 Deals by Key Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Value and Year
7.2.2 Deals by Key Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Co-development Deals with Disclosed Values

8 Appendix
8.1 References
8.2 Abbreviations
8.3 List of All Pipeline Products
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer

List of Tables
Table 1: Women’s Health Drugs Market, Global, Classification of Cervical Intraepithelial Neoplasia, 2018
Table 2: Women’s Health Drugs Market, Common Symptoms of the Perimenopause and Menopause, 2018
Table 3: Women’s Health Drugs Market, Global, Comparison of PCOS Diagnostic Criteria Classification Systems, 2018
Table 4: Women’s Health Drugs Market, 7MM, Prevalence of Endometriosis, Polycystic Ovarian Syndrome, and Women’s Infertility, 2017
Table 5: Women’s Health Drugs Market, Global, Types of Female Contraceptives, 2018
Table 6: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Premarin, 2018
Table 7: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Lupron/Lupron Depot, 2018
Table 8: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Gonal-F, 2018
Table 9: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Mirena, 2018
Table 10: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Celebrex, 2018
Table 11: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Implanon ,2018
Table 12: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Yasmin/Yaz, 2018
Table 13: Women’s Health Drugs Market, Global, Approved Health Indications for Nuvaring, 2018
Table 14: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Gardasil, 2018
Table 15: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Esmya, 2018
Table 16: Women’s Health Drugs Market, Global, Approved Women’s Health Indications for Orilissa, 2018
Table 17: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024 (part 1)
Table 18: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024 (part 2)
Table 19: Women’s Health Drugs Market, Global, Forecast Revenue by Company, 2017-2024

List of Figures
Figure 1: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Endometriosis, 2017-2024
Figure 2: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Polycystic Ovarian Syndrome, 2017-2024
Figure 3: Women’s Health Drugs Market, 7MM, Epidemiology Patterns for Infertility, 2017-2024
Figure 4: Women’s Health Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
Figure 5: Women’s Health Drugs Market, Global, Annual Revenue for Premarin ($bn), 2006-2024
Figure 6: Women’s Health Drugs Market, Global, Annual Revenue for Lupron ($bn), 2006-2024
Figure 7: Women’s Health Drugs Market, Global, Annual Revenue for Gonal-F ($m), 2017-2024
Figure 8: Women’s Health Market, Global, Annual Revenue for Mirena ($bn), 2006-2024
Figure 9: Women’s Health Drugs Market, Global, Annual Revenue for Celebrex ($bn), 2006-2024
Figure 10: Women’s Health Drugs Market, Global, Annual Revenue for Implanon/Nexplanon ($m), 2007-2024
Figure 11: Women’s Health Drugs Market, Global, Annual Revenue for Yasmin/Yaz ($bn), 2006-2024
Figure 12: Women’s Health Drugs Market, Global, Annual Revenue for Nuvaring ($m), 2006-2024
Figure 13: Women’s Health Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2017-2023
Figure 14: Women’s Health Drugs Market, Global, Annual Revenue for Esmya ($bn), 2013-2024
Figure 15: Women’s Health Drugs Market, Global, Annual Revenue for Orilissa ($bn), 2018-2024
Figure 16: Women’s Health Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 17: Women’s Health Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 18: Women’s Health Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
Figure 19: Women’s Health Market, Global, Pipeline for Key Indications by Molecule Type, 2018
Figure 20: Women’s Health Drugs Market, Global, Pipeline by Molecular Target, 2018
Figure 21: Women’s Health Drugs Market, Global, Pipeline for Key Indications by Molecular Target Class, 2018
Figure 22: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006-2018
Figure 23: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2018
Figure 24: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006-2018
Figure 25: Women’s Health Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target Class (%), 2006-2018
Figure 26: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018
Figure 27: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018
Figure 28: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018
Figure 29: Women’s Health Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target Class (months), 2006-2018
Figure 30: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018
Figure 31: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018
Figure 32: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018
Figure 33: Women’s Health Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018
Figure 34: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018
Figure 35: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018
Figure 36: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018
Figure 37: Women’s Health Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018
Figure 38: Women’s Health Drugs Market, Global, Revenue Forecast for Relugolix ($m), 2021-2024
Figure 39: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Bremelanotide ($m), 2019-2024
Figure 40: Women’s Health Drugs Market, Global, Revenue Forecast for SAGE-217 ($m), 2019-2024
Figure 41: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Fezolinetant ($m), 2021-2024
Figure 42: Women’s Health Drugs Market, Global, Revenue Forecast for Zulresso ($m), 2019-2024
Figure 43: Women’s Health Drugs Market, Global, Revenue Forecast for Bizalimogene Ralaplasmid and Mavilimogene Ralaplasmid ($m), 2021-2024
Figure 44: Women’s Health Drugs Market, Global, Revenue Forecast for Retosiban ($m), 2019-2024
Figure 45: Women’s Health Drugs Market, Global, Market Size ($bn), 2017-2024
Figure 46: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024
Figure 47: Women’s Health Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Target Class ($bn), 2017-2024
Figure 48: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Nuclear Receptor Target Class ($bn), 2017-2024
Figure 49: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Pathogen Target Class ($bn), 2017-2024
Figure 50: Women’s Health Drugs Market, Global, Annual Revenue Forecast for Ion Channels/Transporters ($bn), 2017-2024
Figure 51: Women’s Health Drugs Market, Global, Company Analysis Matrix, 2017-2024
Figure 52: Women’s Health Market, Global, Companies by CAGR and Market Share, 2017-2024
Figure 53: Women’s Health Drugs Market, Global, Market Share by Company (%), 2017-2024
Figure 54: Women’s Health Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024
Figure 55: Women’s Health Market, Global, Revenues by Route of Acquisition, 2017-2024
Figure 56: Women’s Health Drugs Market, Global, Bayer AG Annual Revenue Forecast ($bn), 2017-2024
Figure 57: Women’s Health Market, Global, AbbVie Inc Annual Revenue Forecast ($bn), 2017-2024
Figure 58: Women’s Health Market, Global, Allergan Plc Annual Revenue Forecast ($bn), 2017-2024
Figure 59: Women’s Health Market, Global, Merck& Co. Annual Revenue Forecast ($bn), 2017-2024
Figure 60: Women’s Health Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2016-2023

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Allergan Plc
  • Bayer AG
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer
  • Therapeutics MD
Note: Product cover images may vary from those shown
Adroll
adroll